Business Context and Reporting Period
Company: Impact BioMedical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2024
Business Overview: The Company focuses on drug discovery and the development of biomedical technologies, including the "Linebacker" therapeutic platform, "Laetose" sugar substitute, "3F" functional fragrance, and "Equivir" antiviral medication. The Company is currently preparing for an Initial Public Offering (IPO) and has been approved for listing on the NYSE American.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | Balance Sheet (June 30, 2024) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(884,000) | $(1,880,000) | N/A |
| Net Loss Attributable to Common Stockholders | $(889,000) | $(1,849,000) | N/A |
| Operating Expenses | $626,000 | $1,396,000 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $2,000 |
| Total Assets | N/A | N/A | $44,116,000 |
| Total Liabilities | N/A | N/A | $17,734,000 |
| Related Party Debt (Note Payable) | N/A | N/A | $13,452,000 |
| Goodwill | N/A | N/A | $25,093,000 |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by 21% for the three months ended June 30, 2024, compared to the same period in 2023, and by 5% for the six-month period. This improvement is attributed to cost-cutting measures.
- Expense Fluctuations:
- Compensation: Sales, general, and administrative compensation increased 254% (QoQ) and 260% (YoY) due to costs associated with SEC registration and IPO preparation.
- Professional Fees: Decreased 59% (QoQ) and 35% (YoY) as the Company anticipates the IPO.
- R&D: Research and development expenses decreased 100% (QoQ) and 89% (YoY) following the termination of a research contract with GRDG in late 2023.
- Debt Increase: The related party note payable increased from $12,074,000 at December 31, 2023, to $13,452,000 at June 30, 2024, driven by additional borrowings to fund operations.
- Interest Expense: Increased 125% for the three months ended June 30, 2024, due to the higher outstanding debt balance.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that the Company's operating losses and negative cash flows raise substantial doubt about its ability to continue as a going concern. Continued operations depend on funding from the majority shareholder (DSS, Inc.) and the successful completion of an IPO.
- Liquidity: Cash on hand is critically low at $2,000. The Company relies on a revolving promissory note with DSS, Inc., extended to September 30, 2030, to meet liquidity needs.
- Capital Strategy: Management plans to monetize intellectual property and control operating costs. The Company has engaged an underwriter and is pursuing an IPO on the NYSE American.
- Subsequent Events: On July 24, 2024, the promissory note with DSS was amended to allow the Company to make payments using Company stock at $3 per share for the first 12 months post-IPO.
- Internal Controls: The Company disclosed material weaknesses in internal controls over financial reporting that remained as of June 30, 2024.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2,000 cash balance against monthly burn rates and the reliability of the related-party funding commitment.
- IPO Status: Confirm the current status of the NYSE American listing approval and the timeline for the Initial Public Offering.
- Related Party Debt: Review the terms of the $13.45 million note payable to DSS, Inc., including the recent amendment allowing stock payments and the potential for dilution.
- Revenue Generation: Assess the progress of licensing agreements (e.g., 3F with Chemia, Equivir) as the Company currently has zero revenue.
- Goodwill Valuation: Evaluate the $25.1 million goodwill balance against the Company's current lack of profitability and potential impairment risks.